Question mark

We at Med Ad News don’t claim to know all the questions. So we challenged our contributors to come up with their own questions and answer them.

Money

Even as they are gathering proof of extensive benefits to patients, the manufacturers of GLP-1s will have to overcome supply chain difficulties and high prices to get payers to fund these medicines for treating obesity.

Ellen Cappellino, Klick Health

Med Ad News chats with Ellen Cappellino, executive director of value, access & reimbursement strategy at Klick Health about the obesity drug market and payer attitudes towards the GLP-1s.

drug development, trials

Merger and acquisition activity is on the rise after the biopharma industry moved on from the COVID-19 pandemic, while the role of AI in drug development is reaching new levels.

Jane Reed, IQVIA

MedAdNews talked to Jane Reed, director of life sciences with Linguamatics, an IQVIA company, about how pharma companies are using new AI-based technologies to advance their safety processes and other topics.

Orr Inbar, Quant Health

2024 will be the year that AI integration will be pivotal to the continued success of those working throughout biotech and life sciences, especially for those involved in the drug discovery and regulation processes.

Short- and long-term use cases recommended by experts.

Neurolief, Relivion

Viz.ai continues to demonstrate significant real-world evidence on the patient and economic outcomes of AI-powered care coordination; Neurolief’s neuromodulation device Relivion is approved by the Japanese Ministry of Health, Labor and Welfare; and Kanerika partners with Microsoft to build an enterprise business intelligence platform powered by Microsoft Fabric for a leading global pharmaceutical company in the United States.

Most medtech companies can’t seamlessly exchange product information between in-country and global regulatory assurance teams, according to the 2023 Regulatory Benchmark Report from Veeva MedTech. Without a standardized and consistent way to share documents globally, organizations can’t ensure the reliability or accuracy of product information across markets. This increases compliance risk.